AIM: To evaluate efficacy of Ranibizumab and Conbercept for wet age-related macular degeneration(wAMD).

METHODS: This was a retrospective case series study. Thirty patients(30 eyes)with wAMD were enrolled to receive intravitreal injections of ranibizumab(0.5mg)on 3 consecutive monthly schedule and 28 patients(30 eyes)with wAMD were enrolled to receive intravitreal injections of conbercept(0.5mg)on 3 consecutive monthly schedule. Best corrected visual acuity(BCVA), optic coherence tomography(OCT)measurement were compared at 1mo after injections.

RESULTS: One month after every injection, the BCVA increased while the central macular thickness(CMT)decreased compared with those before treatment in group A and B(P<0.05). BCVA and CMT changes between two groups were no statistically different(P>0.05).

CONCLUSION:Ranibizumab and conbercept therapy can control the prognosis of wAMD and improve the vision effectively. There is no statistical difference on the curative effect between two drugs for 3mo.